Vis enkel innførsel

dc.contributor.authorKrantz, Christina
dc.contributor.authorAccordini, Simone
dc.contributor.authorAlving, Kjell
dc.contributor.authorCorsico, Angelo G.
dc.contributor.authorDemoly, Pascal
dc.contributor.authorFerreira, Diogenes S.
dc.contributor.authorForsberg, Bertil
dc.contributor.authorGarcia-Aymerich, Judith
dc.contributor.authorGislason, Thorarinn
dc.contributor.authorHeinrich, Joachim
dc.contributor.authorJõgi, Rain
dc.contributor.authorJohannessen, Ane
dc.contributor.authorLeynaert, Bénédicte
dc.contributor.authorMarcon, Alessandro
dc.contributor.authorMartínez-Moratalla Rovira, Jesús
dc.contributor.authorNerpin, Elisabet
dc.contributor.authorNowak, Dennis
dc.contributor.authorOlin, Anna-Carin
dc.contributor.authorOlivieri, Mario
dc.contributor.authorPereira-Vega, Antonio
dc.contributor.authorRaherison-Semjen, Chantal
dc.contributor.authorReal, Francisco Gomez
dc.contributor.authorSigsgaard, Torben
dc.contributor.authorSquillacioti, Giulia
dc.contributor.authorJanson, Christer
dc.contributor.authorMalinovschi, Andrei
dc.date.accessioned2022-04-01T11:56:13Z
dc.date.available2022-04-01T11:56:13Z
dc.date.created2022-02-04T07:53:01Z
dc.date.issued2022
dc.identifier.issn0954-7894
dc.identifier.urihttps://hdl.handle.net/11250/2989284
dc.description.abstractBackground: Fractional exhaled nitric oxide (FeNO) is a well-known marker of type-2 inflammation. FeNO is elevated in asthma and allergic rhinitis, with IgE sensitization as a major determinant. Objective: We aimed to see whether there was an independent association between upper airway inflammatory disorders (UAID) and FeNO, after adjustment for asthma and sensitization, in a multi-centre population-based study. Methods: A total of 741 subjects with current asthma and 4155 non-asthmatic subjects participating in the second follow-up of the European Community Respiratory Health Survey (ECRHS III) underwent FeNO measurements. Sensitization status was based on measurement of IgE against airborne allergens; information on asthma, UAID and medication was collected through interview-led questionnaires. Independent associations between UAID and FeNO were assessed in adjusted multivariate regression models and test for interaction with perennial sensitization and asthma on the relation between UAID and FeNO were made. Results: UAID were associated with higher FeNO after adjusting for perennial sensitization, asthma and other confounders: with 4.4 (0.9–7.9) % higher FeNO in relation to current rhinitis and 4.8 (0.7–9.2) % higher FeNO in relation to rhinoconjunctivitis. A significant interaction with perennial sensitization was found in the relationship between current rhinitis and FeNO (p = .03) and between rhinoconjunctivitis and FeNO (p = .03). After stratification by asthma and perennial sensitization, the association between current rhinitis and FeNO remained in non-asthmatic subjects with perennial sensitization, with 12.1 (0.2–25.5) % higher FeNO in subjects with current rhinitis than in those without. Conclusions & Clinical Relevance: Current rhinitis and rhinoconjunctivitis was associated with higher FeNO, with an interaction with perennial sensitization. This further highlights the concept of united airway disease, with correlations between symptoms and inflammation in the upper and lower airways and that sensitization needs to be accounted for in the relation between FeNO and rhinitis.en_US
dc.language.isoengen_US
dc.publisherWileyen_US
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 Internasjonal*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/deed.no*
dc.titleCross-sectional study on exhaled nitric oxide in relation to upper airway inflammatory disorders with regard to asthma and perennial sensitizationen_US
dc.typeJournal articleen_US
dc.typePeer revieweden_US
dc.description.versionpublishedVersionen_US
dc.rights.holderCopyright 2021 the authorsen_US
cristin.ispublishedtrue
cristin.fulltextoriginal
cristin.qualitycode1
dc.identifier.doi10.1111/cea.14019
dc.identifier.cristin1997630
dc.source.journalClinical and Experimental Allergyen_US
dc.source.pagenumber297-311en_US
dc.identifier.citationClinical and Experimental Allergy. 2022, 52 (2), 297-311 .en_US
dc.source.volume52en_US
dc.source.issue2en_US


Tilhørende fil(er)

Thumbnail

Denne innførselen finnes i følgende samling(er)

Vis enkel innførsel

Attribution-NonCommercial-NoDerivatives 4.0 Internasjonal
Med mindre annet er angitt, så er denne innførselen lisensiert som Attribution-NonCommercial-NoDerivatives 4.0 Internasjonal